查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2026886

生物製藥外包市場預測至2034年－按產品類型、類別、原料、服務、應用、最終用戶和地區分類的全球分析

Biologics Outsourcing Market Forecasts to 2034 - Global Analysis By Product (Antibodies, Vaccines, Recombinant Proteins and Other Products), Type (Instruments and Kits & Reagents), Source, Service, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球生技藥品外包市場規模將達到 371 億美元，並在預測期內以 16.0% 的複合年成長率成長，到 2034 年將達到 1,217 億美元。

生物製藥外包是指生物製藥產業在生物製藥開發、生產或研究的各個階段，將專業服務委託給外部合作夥伴（例如合約研究組織 (CRO) 和契約製造組織 (CMO)）的做法。其目標包括簡化營運、降低成本、縮短開發週期、獲取專業資源以及擴大市場上可用的生物製藥療法組合。

根據世界衛生組織（世衛組織）的說法，COVID-19是由嚴重急性呼吸道症候群冠狀病毒2（SARS-CoV-2）感染疾病的高度傳染性感染疾病。截至2023年2月15日，全球約有756,291,327人感染。

生物製藥研發的擴展

製藥公司日益重視開發用於治療包括癌症和自體免疫疾病在內的多種疾病的生物製藥。這種研發投入的活性化需要專業的知識和基礎設施，因此，將研發和生產外包給合約研究組織 (CRO) 和合約受託製造廠商(CMO) 的趨勢日益明顯。此外，外包能夠利用外部資源，縮短藥物研發週期，並提供專業資源，從而加速創新並擴大生物製藥治療方法的類型。

品管與保證

確保不同外包合作夥伴之間品質標準的一致性和嚴格性是一項挑戰。對於生物製藥尤其如此，因為其生產要求複雜，難以協調品管措施並維持生產過程的一致性。合作夥伴之間品質保證實踐的不一致會影響生物製藥的可靠性和一致性，進而可能引發人們對產品療效和安全性的擔憂。

先進技術與創新

生物製程技術的快速發展，包括一次性系統、連續生產和基因編輯工具，為外包合作夥伴提供了採用前沿創新並將其融入自身服務產品的機會。透過擁抱這些進步，外包公司可以提升其在生物製藥開發、生產和品管方面的能力。此外，透過投資和利用這些最尖端科技，外包合作夥伴可以提供獨特且具競爭力的服務，吸引尋求最尖端科技的客戶，並在瞬息萬變的生物製藥開發和生產市場中獲得成長前景。

依賴外部專業知識

過度依賴外部專業知識對生物製藥外包市場構成重大威脅。過度依賴外包夥伴進行研發和生產等關鍵職能，會限制企業內部對生技製藥生產流程的了解與控制。這種對外部專業知識的過度依賴會導致缺乏柔軟性、更容易受到干擾，以及難以敏捷地應對瞬息萬變的市場需求。

新冠疫情的影響

新冠疫情對生物製藥外包市場產生了重大影響。疫情的主要影響是生物製藥需求激增，進而導致外包服務需求大幅上升。為了因應研發有效疫苗和治療方法的迫切需求，許多製藥公司已將部分業務外包給專業的合約研發生產機構（CDMO），以滿足其生物製藥的生產和研發需求。為了確保生物製藥的穩定供應，這次疫情迫使許多製藥公司探索其他外包途徑。

在預測期內，抗體細分市場預計將是規模最大的。

抗體領域預計將佔據最大的市場佔有率。抗體作為治療藥物，針對導致疾病的特定分子，可用於治療包括感染疾病、自體免疫疾病和癌症在內的多種疾病。抗體廣泛應用於藥物發現與開發、標靶檢驗、蛋白質表徵和定量等諸多領域。此外，外包抗體生產能夠幫助企業專注於自身核心優勢，例如藥物發現、臨床前和臨床研究以及其他研發活動，同時確保合規性並降低監管風險。

在預測期內，腫瘤領域預計將呈現最高的複合年成長率。

預計在預測期內，腫瘤領域將迎來顯著成長。生物製藥為癌症治療提供標靶和個人化的治療方案，在對抗各種惡性腫瘤方面展現出極高的療效。合約研究組織 (CRO) 和受託製造廠商(CMO) 為腫瘤相關生物製藥提供專業支持，包括單株抗體、免疫療法和標靶治療。此外，隨著越來越多的製藥公司專注於腫瘤藥物研發，該領域對外包服務的需求預計將大幅成長。

市佔率最大的地區：

在估算期間內，亞太地區佔據了最大的市場佔有率。該地區生物製藥行業的成長、有利的法規環境以及研發投入的增加，正在推動市場擴張。此外，成本效益、創新能力以及能夠接觸到多元化的患者群體等競爭優勢，也促成了亞太地區生物製藥生產外包市場的蓬勃發展，其中包括合約研發和生產服務。該地區在全球生物製藥外包市場中繼續發揮著至關重要的作用，推動著產業的成長和創新。

複合年成長率最高的地區：

由於北美擁有完善的醫療保健基礎設施、先進的研發設施以及對創新的高度重視，預計該地區在預測期內將實現盈利成長。此外，隨著疫苗、細胞療法和單株抗體等生物製藥產品需求的不斷成長，以及內部生產成本的居高不下，製藥和生物技術公司正擴大將生物製藥生產流程外包。北美憑藉其優越的地理位置和豐富的高技能勞動力，成為生物製藥外包的熱門目的地。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章：執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球生物製藥外包市場：依產品分類

  • 抗體
  • 疫苗
  • 重組蛋白
  • 其他產品

第6章：全球生物製藥外包市場：依類型分類

  • 裝置
  • 試劑盒和試劑

第7章 全球生物製藥外包市場：依來源分類

  • 微生物來源
  • 哺乳動物

第8章 全球生物製藥外包市場：依服務類型分類

  • 細胞發育
  • 分析測試
  • 製程開發
  • cGMP生產
  • 其他服務

第9章 全球生物製藥外包市場：依應用領域分類

  • 腫瘤學
  • 血液及血液製品的開發
  • 細胞和基因治療
  • 幹細胞研究
  • 疫苗和治療藥物的研發
  • 其他用途

第10章：全球生物製藥外包市場：以最終用戶分類

  • 製藥業
  • CDMO
  • 生技產業

第11章 全球生物製藥外包市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第12章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第13章：公司簡介

  • Thermo Fisher Scientific Inc
  • Adimab LLC
  • Abzena Ltd.
  • KBI Biopharma
  • Curia Global, Inc.
  • EirGenix, Inc.
  • Bionova Scientific, Inc.
  • Boehringer Ingelheim International GmbH.
  • Abbvie Inc.
  • STC Biologics
  • Avid Bioservices, Inc.
  • Catalent Inc.
  • Genentech, Inc.
  • Eurofins Scientific
  • Genscript Biotech Corporation
  • Lonza
  • JSR Corporation
  • Merck KGaA
  • Rentschler Biopharma SE
  • Emergent
Product Code: SMRC24732

According to Stratistics MRC, the Global Biologics Outsourcing Market is accounted for $37.1 billion in 2026 and is expected to reach $121.7 billion by 2034 growing at a CAGR of 16.0% during the forecast period. Biologics Outsourcing refers to the practice of contracting specialized services in the biopharmaceutical industry to external partners, such as contract research organizations (CROs) and contract manufacturing organizations (CMOs), for various stages of biologic drug development, manufacturing, or research. It aims to streamline operations, reduce costs, accelerate timelines, access specialized resources, and expand the portfolio of biologic therapies available in the market.

According to the World Health Organisation (WHO), coronavirus disease 2019 (COVID-19) is a highly contagious infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of February 15, 2023, about 756,291,327 people are affected worldwide.

Market Dynamics:

Driver:

Increasing biologics development

Pharmaceutical companies increasingly focus on biologic drug development for various ailments, like cancer and autoimmune disorders. This heightened development necessitates specialised expertise and infrastructure, driving the outsourcing of research, development, and manufacturing to contract research organisations (CROs) and contract manufacturing organisations (CMOs). Moreover, outsourcing allows for leveraging external capabilities, accelerating drug development timelines, and accessing specialised resources, thereby fostering innovation and expanding the array of available biologic therapies.

Restraint:

Quality control and assurance

Ensuring consistent and stringent quality standards across diverse outsourcing partners poses challenges. Harmonising quality control measures and maintaining uniformity in production processes, especially for biologic drugs with complex manufacturing requirements, can be demanding. Variability in quality assurance practices among different partners might impact the reliability and consistency of biologics, raising concerns about product efficacy and safety.

Opportunity:

Advanced technologies and innovation

The rapid evolution of bioprocessing technologies, such as single-use systems, continuous manufacturing, and gene editing tools, offers outsourcing partners the chance to adopt and integrate cutting-edge innovations into their service offerings. By embracing these advancements, outsourcing firms can enhance their capabilities in biologics development, production, and quality control. Furthermore, investing in and utilising these cutting-edge technologies allows outsourcing partners to provide unique and competitive services that draw in clients looking for cutting-edge technologies and provide growth prospects in the ever-changing biologics development and manufacturing market.

Threat:

Dependency on external expertise

Dependency on external expertise poses a significant threat in the Biologics Outsourcing market. Relying extensively on outsourcing partners for critical functions like research, development, and manufacturing might limit in-house knowledge and control over the biologics production process. Overreliance on external expertise could potentially result in a lack of flexibility, increased vulnerability to disruptions, and reduced agility in responding to dynamic market needs.

Covid-19 Impact

The COVID-19 pandemic had a significant impact on the biologics outsourcing market. The pandemic's primary impact has been a rise in the demand for biologics and the ensuing requirement for outsourcing services. Many pharmaceutical companies are outsourcing to specialised contract development and manufacturing organisations (CDMOs) to handle their biologics manufacturing and development needs due to the emerge to develop effective vaccines and therapies against the virus. In order to guarantee a steady supply of biologics products, this disruption compelled numerous pharmaceutical corporations to search for other outsourcing possibilities.

The antibodies segment is expected to be the largest during the forecast period

The antibodies segment is estimated to hold the largest share. Antibodies are used as therapeutic agents to target particular molecules that cause disease, assisting with the treatment of a variety of diseases such as infectious diseases, autoimmune diseases, and cancer. Antibodies are extensively employed in drug discovery, development, and many other fields for target validation, protein characterization, and quantification. In addition, outsourcing antibodies ensures regulatory compliance and lowers regulatory risks for the companies, allowing them to concentrate on their core strengths, which include drug discovery, pre-clinical and clinical research, and other R&D operations.

The oncology segment is expected to have the highest CAGR during the forecast period

The oncology segment is anticipated to have lucrative growth during the forecast period. Biologics offer targeted and personalised approaches to cancer treatment, making them highly effective in combating various types of malignancies. Contract research organisations (CROs) and contract manufacturing organisations (CMOs) offer specialised support for oncology-related biologics, including monoclonal antibodies, immunotherapies, and targeted therapies. Moreover, with an increasing number of pharmaceutical companies focusing on oncology drug development, the need for outsourcing services in this segment is expected to surge.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period. The region's growing biopharmaceutical industry, favourable regulatory frameworks, and increasing investments in research and development fuel the market's expansion. Furthermore, outsourcing biologics production, including contract research, development, and manufacturing services, thrives in Asia-Pacific due to its competitive advantages in cost-efficiency, innovation, and access to a diverse patient pool. This region continues to play a pivotal role in the global biologics outsourcing landscape, fostering growth and innovation within the industry.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period due to robust healthcare infrastructure, cutting-edge research and development facilities, and a strong emphasis on innovation. Furthermore, the growing need for biologics, such as vaccines, cell treatments, and monoclonal antibodies, has encouraged pharmaceutical and biotechnology companies to outsource their biologic production processes due to the high expense of internal manufacture. North America has become a popular destination for biologics outsourcing due to its advantageous geographic position and plenty of highly skilled labour.

Key players in the market

Some of the key players in the Biologics Outsourcing Market include Thermo Fisher Scientific Inc, Adimab LLC, Abzena Ltd., KBI Biopharma, Curia Global, Inc., EirGenix, Inc., Bionova Scientific, Inc., Boehringer Ingelheim International GmbH., Abbvie Inc., STC Biologics, Avid Bioservices, Inc., Catalent Inc., Genentech, Inc., Eurofins Scientific, Genscript Biotech Corporation, Lonza, JSR Corporation, Merck KGaA, Rentschler Biopharma SE and Emergent.

Key Developments:

In December 2022, AbbVie partnered with AbCellera Biologics Inc. The partnership leverage AbCellera's antibody discovery and development engine to deliver optimized development candidates for up to five targets selected by AbbVie across multiple indications. This helped the company to enhance its service offerings.

In December 2022, Thermo Fisher expanded its biologics and steriles manufacturing capabilities in China. The facility offers integrated clinical and commercial drug substance and drug product capabilities. This includes process development, cell line development, biologics drug substance manufacturing, and sterile fill-finish. This helped the company expand its geographic presence.

Products Covered:

  • Antibodies
  • Vaccines
  • Recombinant Proteins
  • Other Products

Types Covered:

  • Instruments
  • Kits & Reagents

Sources Covered:

  • Microbial
  • Mammalian

Services Covered:

  • Cell Development
  • Analytical Testing
  • Process Development
  • CGMP Manufacturing
  • Other Services

Applications Covered:

  • Oncology
  • Blood & Blood-Related Products Development
  • Cellular and Gene Therapy
  • Stem Cell Research
  • Vaccine and Therapeutics Development
  • Other Applications

End Users Covered:

  • Pharmaceutical Industries
  • CDMO
  • Biotechnology Industries

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Biologics Outsourcing Market, By Product

  • 5.1 Introduction
  • 5.2 Antibodies
  • 5.3 Vaccines
  • 5.4 Recombinant Proteins
  • 5.5 Other Products

6 Global Biologics Outsourcing Market, By Type

  • 6.1 Introduction
  • 6.2 Instruments
  • 6.3 Kits & Reagents

7 Global Biologics Outsourcing Market, By Source

  • 7.1 Introduction
  • 7.2 Microbial
  • 7.3 Mammalian

8 Global Biologics Outsourcing Market, By Service

  • 8.1 Introduction
  • 8.2 Cell Development
  • 8.3 Analytical Testing
  • 8.4 Process Development
  • 8.5 cGMP Manufacturing
  • 8.6 Other Services

9 Global Biologics Outsourcing Market, By Application

  • 9.1 Introduction
  • 9.2 Oncology
  • 9.3 Blood & Blood-Related Products Development
  • 9.4 Cellular and Gene Therapy
  • 9.5 Stem Cell Research
  • 9.6 Vaccine and Therapeutics Development
  • 9.7 Other Applications

10 Global Biologics Outsourcing Market, By End User

  • 10.1 Introduction
  • 10.2 Pharmaceutical Industries
  • 10.3 CDMO
  • 10.4 Biotechnology Industries

11 Global Biologics Outsourcing Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Thermo Fisher Scientific Inc
  • 13.2 Adimab LLC
  • 13.3 Abzena Ltd.
  • 13.4 KBI Biopharma
  • 13.5 Curia Global, Inc.
  • 13.6 EirGenix, Inc.
  • 13.7 Bionova Scientific, Inc.
  • 13.8 Boehringer Ingelheim International GmbH.
  • 13.9 Abbvie Inc.
  • 13.10 STC Biologics
  • 13.11 Avid Bioservices, Inc.
  • 13.12 Catalent Inc.
  • 13.13 Genentech, Inc.
  • 13.14 Eurofins Scientific
  • 13.15 Genscript Biotech Corporation
  • 13.16 Lonza
  • 13.17 JSR Corporation
  • 13.18 Merck KGaA
  • 13.19 Rentschler Biopharma SE
  • 13.20 Emergent

List of Tables

  • Table 1 Global Biologics Outsourcing Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Biologics Outsourcing Market Outlook, By Product (2023-2034) ($MN)
  • Table 3 Global Biologics Outsourcing Market Outlook, By Antibodies (2023-2034) ($MN)
  • Table 4 Global Biologics Outsourcing Market Outlook, By Vaccines (2023-2034) ($MN)
  • Table 5 Global Biologics Outsourcing Market Outlook, By Recombinant Proteins (2023-2034) ($MN)
  • Table 6 Global Biologics Outsourcing Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 7 Global Biologics Outsourcing Market Outlook, By Type (2023-2034) ($MN)
  • Table 8 Global Biologics Outsourcing Market Outlook, By Instruments (2023-2034) ($MN)
  • Table 9 Global Biologics Outsourcing Market Outlook, By Kits & Reagents (2023-2034) ($MN)
  • Table 10 Global Biologics Outsourcing Market Outlook, By Source (2023-2034) ($MN)
  • Table 11 Global Biologics Outsourcing Market Outlook, By Microbial (2023-2034) ($MN)
  • Table 12 Global Biologics Outsourcing Market Outlook, By Mammalian (2023-2034) ($MN)
  • Table 13 Global Biologics Outsourcing Market Outlook, By Service (2023-2034) ($MN)
  • Table 14 Global Biologics Outsourcing Market Outlook, By Cell Development (2023-2034) ($MN)
  • Table 15 Global Biologics Outsourcing Market Outlook, By Analytical Testing (2023-2034) ($MN)
  • Table 16 Global Biologics Outsourcing Market Outlook, By Process Development (2023-2034) ($MN)
  • Table 17 Global Biologics Outsourcing Market Outlook, By cGMP Manufacturing (2023-2034) ($MN)
  • Table 18 Global Biologics Outsourcing Market Outlook, By Other Services (2023-2034) ($MN)
  • Table 19 Global Biologics Outsourcing Market Outlook, By Application (2023-2034) ($MN)
  • Table 20 Global Biologics Outsourcing Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 21 Global Biologics Outsourcing Market Outlook, By Blood & Blood-Related Products Development (2023-2034) ($MN)
  • Table 22 Global Biologics Outsourcing Market Outlook, By Cellular and Gene Therapy (2023-2034) ($MN)
  • Table 23 Global Biologics Outsourcing Market Outlook, By Stem Cell Research (2023-2034) ($MN)
  • Table 24 Global Biologics Outsourcing Market Outlook, By Vaccine and Therapeutics Development (2023-2034) ($MN)
  • Table 25 Global Biologics Outsourcing Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 26 Global Biologics Outsourcing Market Outlook, By End User (2023-2034) ($MN)
  • Table 27 Global Biologics Outsourcing Market Outlook, By Pharmaceutical Industries (2023-2034) ($MN)
  • Table 28 Global Biologics Outsourcing Market Outlook, By CDMO (2023-2034) ($MN)
  • Table 29 Global Biologics Outsourcing Market Outlook, By Biotechnology Industries (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.